The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBanco Santander Regulatory News (BNC)

Share Price Information for Banco Santander (BNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 407.50
Bid: 401.50
Ask: 414.50
Change: 0.00 (0.00%)
Spread: 13.00 (3.238%)
Open: 411.00
High: 413.50
Low: 404.00
Prev. Close: 407.50
BNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MREL Resolution Group Banco Santander

28 Nov 2019 18:17

RNS Number : 0690V
Banco Santander S.A.
28 November 2019
 

 

 

 

Banco Santander, S.A. ("Santander"), pursuant to the Securities Market Law, hereby announces the following:

 

INSIDE INFORMATION

 

The Bank of Spain has formally notified the binding minimum requirement for eligible liabilities and own funds ("MREL"), both total and subordinated, for the resolution group headed by Santander[1] (the "Resolution Group"), as determined by the Single Resolution Board ("SRB"). On 1 January 2020, this requirement will replace the one that was applicable previously and that was announced through a material fact on 24 May 2018 (CNMV registration number 266090).

The MREL requirement has been set in terms of the Resolution Group's total liabilities and own funds ("TLOF"). It consists of a requirement for eligible liabilities as a percentage of TLOF ("Total MREL") and, within this, a requirement for eligible liabilities with subordination as a percentage of TLOF ("Subordinated MREL").

For ease of understanding, the table below includes an equivalent percentage in risk-weighted assets and an equivalent amount using data as at 31 December 2017 (the date used by the SRB for calibrating the MREL requirement). It also includes, for comparison purposes, the Total MREL requirement announced in the previous material fact, and the equivalent percentage and amount for this requirement:

 

Requirement in terms of total liabilities and own funds

Equivalent percentage in risk-weighted assets at 31/12/17

Equivalent amount

(EUR million) at 31/12/17

Total MREL

Communicated on

28/11/19

16.81%

28.60%

108,631.80

Subordinated MREL[2]

Communicated on

28/11/19

11.48%

19.53%

74,187.57

 

 

 

 

Requirement in terms of total liabilities and own funds

Equivalent percentage in risk-weighted assets at 31/12/16

Equivalent amount

(EUR million) at 31/12/16

MREL previously announced on 24/05/18

22.90%

24.35%

114,482.84

 

The variation in the MREL requirement with respect to 2018 is accounted for mainly by two factors: (i) a change in the scope of consolidation of the Resolution Group, which now includes new companies; and (ii) a modification in the calculation of capital consumption due to equity risk; changes that have led to a reduction in the risk-weighted assets of the Resolution Group.

According to our estimates, the Resolution Group complies with the new MREL requirement and the subordination requirement. Future requirements are subject to ongoing review by the resolution authority.

 

 

Boadilla del Monte, Madrid, 28 November 2019

 

[1]The Resolution Group comprises Banco Santander, S.A. and the entities that belong to the same European resolution group, mainly the entities of the sub-group headed by Santander Consumer Finance. S.A.

At 31 December 2017, the Resolution Group had risk-weighted assets amounting to EUR 379,835 million and TLOF amounting to EUR 646,233 million.

[2]The SRB considers that the subordination requirement can be covered by non-subordinated instruments in an amount equivalent to 2.5% of risk-weighted assets, 1.47% in terms of TLOF, having considered the absence of material adverse impact on resolvability. If this allowance were taken into account, the requirement that would have to be covered by subordinated instruments would be 10.01% in terms of TLOF and 17.03% in terms of RWAs, using data as of December 2017 as a reference.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMMZMRRDGLZM
Date   Source Headline
23rd Apr 202411:03 amRNSNotice of First Quarter 2024 Results
18th Apr 202411:04 amRNSBuyback programme: transactions 11-17 Apr
11th Apr 202411:07 amRNSBuyback programme: transactions 3-10 Apr
3rd Apr 202411:10 amRNSBuyback programme: transactions 21Mar-2Apr
2nd Apr 20245:07 pmRNSTotal Voting Rights
22nd Mar 20242:27 pmRNS2024 AGM - Resolutions
22nd Mar 20247:00 amRNSSantander is on its track to meet its 2024 targets
21st Mar 202410:52 amRNSBuyback programme: transactions 14-20 Mar
19th Mar 20249:47 amRNS2023 UK Annual Report
18th Mar 20245:46 pmRNSDirector/PDMR Shareholding
18th Mar 20245:37 pmRNSDirector/PDMR Shareholding
18th Mar 20245:26 pmRNSDirector/PDMR Shareholding
14th Mar 202411:04 amRNSBuyback programme: transactions 7-13 Mar
12th Mar 20249:30 amRNSForm 8.3 - Spirent Communications plc
7th Mar 202411:05 amRNSBuyback programme: transactions 29 Feb-6 Mar
29th Feb 20242:50 pmRNSTotal Voting Rights
29th Feb 202411:07 amRNSBuyback programme: transactions 20-28 Feb
27th Feb 20245:15 pmRNSDirector/PDMR Shareholding
27th Feb 20245:13 pmRNSDirector/PDMR Shareholding
27th Feb 20245:12 pmRNSDirector/PDMR Shareholding
21st Feb 20243:33 pmRNSDirector/PDMR Shareholding
20th Feb 20247:00 amRNSNotice of AGM
19th Feb 202411:17 amRNSDividend approval & buyback program implementation
19th Feb 20247:45 amRNSFurther re dividend approval
19th Feb 20247:43 amRNSDividend approval & buyback program implementation
7th Feb 20244:39 pmRNSDirector/PDMR Shareholding
7th Feb 20244:38 pmRNSDirector/PDMR Shareholding
7th Feb 20244:36 pmRNSDirector/PDMR Shareholding
5th Feb 20245:48 pmRNSFurther re capital reduction
1st Feb 20244:46 pmRNSDirector/PDMR Shareholding
31st Jan 20243:55 pmRNSTotal Voting Rights
31st Jan 20247:00 amRNS2023 Results - Press release
31st Jan 20247:00 amRNS2023 Results Report & Earnings Presentation
26th Jan 202411:32 amRNSCapital reduction following completion of program
26th Jan 202411:19 amRNSTransaction in Own Shares
24th Jan 202411:06 amRNSNotice of 2023 Results Presentation
18th Jan 202411:05 amRNSBuyback programme: transactions 11-17 Jan
11th Jan 202411:08 amRNSBuyback programme: transactions 4-10 Jan
4th Jan 202411:07 amRNSBuyback programme: transactions 28 Dec- 3 Jan
29th Dec 202311:58 amRNSTotal Voting Rights
28th Dec 202311:08 amRNSBuyback programme: transactions 21-27 Dec
21st Dec 202311:07 amRNSBuyback programme: transactions 14-20 Dec
20th Dec 20234:14 pmRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSAdapting reporting to new operating model (ppt)
20th Dec 20237:00 amRNSAdapting reporting to new operating model (PR)
18th Dec 20235:22 pmRNSDirector/PDMR Shareholding
18th Dec 20235:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:05 amRNSDirector/PDMR Shareholding
14th Dec 202311:05 amRNSBuyback programme: transactions 5-13 Dec
13th Dec 20234:41 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.